CBMG News Alert Cellular Biomedicine Group Inc. (CBMG) 21.00

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellular Biomedicine Group Inc. (CBMG) 21.00 $CBMG

Cellular Biomedicine Group Completes Acquisition of Agreen Biotech Co Ltd.
GlobeNewswire - Tue Sep 30, 8:15AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced it has completed the previously announced acquisition of privately held Agreen Biotech Co. Ltd. China ("AG" and its founder's U.S. patent.

Spinal Muscular Atrophy (SMA) Therapeutics Pipeline Review 2014 - 17 Companies & 27 Drug Profiles
M2 - Fri Sep 12, 3:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r5vn8b/spinal_muscular) has announced the addition of the "Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Muscular Atrophy (SMA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Genzyme Corporation - F. Hoffmann-La Roche Ltd. - Isis Pharmaceuticals, Inc. - Pfizer Inc. - Zambon Company S.p.A. - Paratek Pharmaceuticals, Inc. - Cytokinetics, Inc. - Neurotune AG - Trophos SA - Nexgenix Pharmaceuticals, LLC - Genethon - Vybion, Inc. - OrphageniX, Inc. - Retrophin, LLC - Neurodyn Inc. - GMP-Orphan SAS - Cellular Biomedicine Group, Inc. Drug Profiles - olesoxime - ISIS-SMNRx - PF-06687859 - RG-7800 - Gene Therapy to Activate SMN for Spinal Muscular Atrophy - AAV9-SMN Gene Therapy - tirasemtiv - PTK-SMA-2 - NXD-30001 - DNA Oligonucleotides for Spinal Muscular Atrophy - RE-003 - Gene Therapy for Spinal Muscular Atrophy - ND-602 - Antisense Oligonucleotide for Spinal Muscular Atrophy and Myotonic Dystrophy - Motor Neuron Precursor Cells - Small Molecule to Activate SMN Protein for Spinal Muscular Atrophy - Agrin Biologic For SMA - sodium phenylbutyrate - Small Molecules for CNS Disorders - PMO-25 - Synthetic Peptides for Central Nervous System Disorders - BBrm-01 - Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - INT-41 - Antisense Oligonucleotides for Spinal Muscular Atrophy - ZP-037 For more information visit http://www.researchandmarkets.com/research/r5...l_muscular

Cellular Biomedicine Group Completes Twelve-Month Follow-Up of Patients From Phase I/IIa Clinical Trial for ReJoin(TM) Therapy for Knee Osteoarthritis
GlobeNewswire - Wed Sep 10, 7:00AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the completion of the twelve-month follow-up of patients from the Phase I/IIa trial, which evaluates the safety and efficacy of the Company's proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoin for Knee Osteoarthritis (KOA).

Cellular Biomedicine Group Launches Clinical Research Study for Cartilage Defect Stem Cell Therapy
GlobeNewswire - Tue Sep 02, 8:58AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the launch of a study on human adipose derived mesenchymal progenitor cell (haMPC) therapy for Cartilage Defects (CD) resulting from osteoarthritis (OA) or sports injury. Both arthroscopy and the use of magnetic resonance imaging (MRI) will be deployed to further demonstrate the regenerative efficacy of ReJoin on cartilage defects.

Cellular Biomedicine Group to Present at Rodman & Renshaw Annual Global Investment Conference
GlobeNewswire - Wed Aug 27, 8:23AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Dr. William (Wei) Cao, CEO, will be presenting at the Rodman & Renshaw 16 Annual Global Investment Conference on Tuesday, September 9 at 4:10 P.M. EDT. The conference is being held September 8-10, 2014 at the New York Palace Hotel in New York City. A live audio webcast of the presentation will be available by accessing http://wsw.com/webcast/rrshq24/​.

Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Fri Aug 15, 9:00AM CDT
What:

Cellular Biomedicine Group Reports Second Quarter and First Half 2014 Financial Results and Provides Business Highlights
GlobeNewswire - Thu Aug 14, 10:58AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today reported financial results for the three and six months ended June 30, 2014 and provided business highlights including the six-month data from its Phase I/IIa clinical trial for ReJoin treatment for Knee Osteoarthritis (KOA).

Cellular Biomedicine Group Completes Patient Treatment in Phase IIb Clinical Trial for ReJoin(TM) Therapy for Knee Osteoarthritis
GlobeNewswire - Tue Aug 12, 8:02AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" today announced that it has treated the final patient in its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoin for Knee Osteoarthritis (KOA).

Cellular Biomedicine Group to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Mon Aug 11, 7:00AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" today announced that the Company will ring The NASDAQ Stock Market Closing Bell on Monday, August 18, 2014 at 4:00 P.M. EDT. A live webcast will be available at https://new.livestream.com/nasdaq/live.

Cellular Biomedicine Group Announces Acquisition of Immune Cell Therapy Technology and U.S. Patent
GlobeNewswire - Mon Aug 04, 8:16AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced reaching an agreement to acquire Agreen Biotech Co. Ltd. China ("AG" and its founder's U.S. patent for a total cash and equity consideration of $3.28 million in cash, the issuance of 753,522 shares of CBMG common stock and the issuance of 75,000 shares of CBMG restricted stock units.

Cellular Biomedicine Group Announces Discontinuation of Consulting Business Segment
GlobeNewswire - Mon Jun 30, 8:05AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the discontinuation of the Company's consulting business segment. The consulting business is expected to be classified as discontinued operations, effective July 1, 2014.

Cellular Biomedicine Group Completes Enrollment in Phase IIb Clinical Trial for ReJoin(TM) Therapy for Knee Osteoarthritis
GlobeNewswire - Thu Jun 26, 7:15AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" today announced that it has completed the patient enrollment required for its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoin for Knee Osteoarthritis (KOA).

Cellular Biomedicine Group Announces Closing of $10 Million Private Placement Offering
GlobeNewswire - Fri Jun 20, 8:58AM CDT
Cellular Biomedicine Group, Inc. (Nasdaq:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the closing of a private placement transaction under which it sold an aggregate of 1,492,537 shares (the "Shares" of the Company's common stock, par value $0.001 per share (the "Common Stock" , to selected private investors (the "Investors" at $6.70 per share, for total gross proceeds of approximately $10 Million.

Cellular Biomedicine Group Releases Positive Six-Month Data From Phase I/IIa Clinical Trial for ReJoin(TM) Treatment of Knee Osteoarthritis (KOA)
GlobeNewswire - Thu Jun 19, 7:30AM CDT
Cellular Biomedicine Group, Inc. (Nasdaq:CBMG) today released the six-month follow-up data analysis of its Phase I/IIa clinical trial for its Rejoin(TM) human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The trial, conducted by Shanghai Renji Hospital, tested the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage.

Cellular Biomedicine Group Commences Trading of Its Common Stock on The NASDAQ Capital Market
GlobeNewswire - Wed Jun 18, 7:00AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, announced today that its common stock commences trading on NASDAQ under the ticker symbol "CBMG" effective today, June 18, 2014.

Cellular Biomedicine Group Approved for Listing on the NASDAQ Capital Market
GlobeNewswire - Mon Jun 16, 7:00AM CDT
Cellular Biomedicine Group Inc. (OTCQB:CBMG) (the "Company" , a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, announced today that its common stock has been approved for listing on the Nasdaq Capital Market and is expected to commence trading on Nasdaq under the ticker symbol "CBMG" on June 18, 2014. The Company's common stock will continue to trade as "CBMG" on the OTCQB until the market closes on June 17, 2014.

Cellular Biomedicine Group Releases Positive Results From Phase I Clinical Trial for Hepatocellular Carcinoma
GlobeNewswire - Mon Mar 24, 11:53AM CDT
Cellular Biomedicine Group, Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce positive results from its Phase I clinical trial, which evaluated the safety of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.

Cellular Biomedicine Group Launches Development Program for Asthma Stem Cell Therapy
GlobeNewswire - Mon Mar 17, 12:28PM CDT
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the launch of their pre-clinical study on human adipose derived mesenchymal progenitor cell (haMPC) therapy for asthma. The study will evaluate the safety and efficacy of haMPCs to treat severe asthma.

Cellular Biomedicine Group Announces Updated Results From Phase I/IIa Clinical Trial for ReJoin(TM) Treatment of Knee Osteoarthritis (KOA)
GlobeNewswire - Mon Feb 24, 10:15AM CST
Cellular Biomedicine Group, Inc. (OTCQB:CBMG) today announced updated analysis of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage. Completed in Q4 2013, the data shows no serious adverse events (SAE), suggesting ReJoin cell therapy for KOA patients is safe.

Cellular Biomedicine Group to Present at New York Stem Cell Summit
GlobeNewswire - Wed Feb 05, 6:24PM CST
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Dr. Wei (William) Cao, Chief Executive Officer, will be presenting at the 9th annual New York Stem Cell Summit. More than 30 of the world's leaders in this rapidly evolving industry will meet on February 18, 2014 at The Convene in New York City to discuss the global stem cell industry outlook and forecast.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 287

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Cambrian Turns Dairy Wastewater Into Long-Term Gas

Updated Category News Views 15

A Wisconsin dairy plant just traded lagoon duty for a 20-year service arrangement, and that is more consequential than the usual shiny renewable-gas headline. Cambrian Innovation says it has commissioned and is operating a wastewater treatment and resource recovery system that handles roughly 280,000 gallons a day. That works out to about 102 million gallons annually, a...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 71

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 102

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 210

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 56

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 180

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Wealth Forum Puts AI and Tokenisation Before Private Wealth

Updated Category News Views 63

Private wealth is about to get squeezed from three directions at once: younger heirs, smarter machines and assets that do not fit neatly in the old family-office binder. That is the real backdrop to the Future of Wealth Forum, a new GFTN and Luxembourg House of Financial Technology partnership slated for Luxembourg City on September 27-29, 2027. It is early days,...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 164

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading

Top 5 Most Recently Viewed Articles

United Bank Secures Crucial $75M Tax Credit for Growth

Updated Category News Views 148

United Bank Receives Significant Tax Credit Allocation United Bank is excited to share that it has been awarded a substantial allocation of $75 million under the New Markets Tax Credit (NMTC) program. This funding, granted by the Department of the Treasury through its affiliated Community Development Entity, UB Community Development, is a testament to the bank's ongoing...

Continue Reading
Exploring Intangible Assets in ASEAN Capital Markets

Updated Category News Views 245

Understanding Intangible Assets in ASEAN Capital Markets Global consulting firm J.S. Held has collaborated with notable organizations to produce an insightful report examining the landscape of intangible assets in ASEAN capital markets. This partnership involves the International Valuation Standards Council (IVSC), the Intellectual Property Office of Singapore (IPOS), and...

Continue Reading
Festival Celebrates Community with Food and Support Services

Updated Category News Views 180

Union Station Homeless Services Teams with Boomtown Brewery Union Station Homeless Services (USHS) collaborates with Boomtown Brewery for a vibrant Summer Sampler Food Festival. This delightful event will showcase not just delicious food but also the spirit of community and cooperation. A Flavorful Afternoon to Remember Taking center stage will be the wide array of...

Continue Reading
Flowable Showcases Cutting-Edge AI Solutions at Gartner Event

Updated Category News Views 260

Flowable Presents Innovative AI Solutions at Gartner Symposium Flowable CEO and CTO to Showcase Responsible AI-Driven Solutions Flowable, a leader in intelligent automation and enterprise transformation, is set to exhibit and present at the renowned Gartner IT Symposium/Xpo 2025 in Barcelona, Spain. This significant gathering of IT professionals will take place from...

Continue Reading
Accounts Receivable Automation Market Set for Major Growth

Updated Category News Views 214

Transforming Financial Management: The Rise of Accounts Receivable Automation As businesses seek operational excellence, the Accounts Receivable (AR) automation market is on a remarkable upswing. It's set to hit USD 3.8 billion by 2033, sporting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2033. This trend signifies a notable change in how companies handle...

Continue Reading